This article provides an update on the drug treatment for heart failure (HF) mostly based on the recent clinical guidelines issued by the National Institute of Clinical Excellence (NICE).1 New high quality evidence from randomised controlled trials has resulted in greater value being given to the use of beta-blockers (BBs) and to the use of the hydralazine-nitrate combination. The importance of monitoring laboratory and clinical parameters to ensure safe and effective drug treatment is also highlighted.peer-reviewe
Aims: Internationally, research indicates that pharmacotherapy for chronic heart failure (CHF) is su...
Heart failure (HF) is a major public health priority due to its epidemiological transition and the w...
Background: Chronic Heart Failure (CHF) has a high mortality and morbidity. Large scale randomised c...
Therapy of heart failure. The incidence and prevalence of heart failure is on the rise. It has becom...
This chapter addresses the state of knowledge in the evidence-based management of heart failure (HF)...
Background: Over the last years, several trials offered new evidence on heart failure (HF) treatment...
Heart failure (HF) is a complex clinical syndrome resulting from any structural or functional cardia...
Abstract Heart failure is one of the major problems related to heart diseases in the modern era. Mul...
International audienceHeart failure is the most common cardiovascular reason for hospital admission ...
Optimal treatment of heart failure is important to reduce hospitalization and mortality. In accordin...
Treatment of heart failure has undergone major changes in the last two decades. European and US guid...
Heart failure with reduced ejection fraction (HFrEF) is a common cardiovascular condition with a sig...
Heart failure (HF) remains a major cause of mortality, morbidity, and poor quality of life. It is an...
Major changes have occurred in these last years in heart failure (HF) management. Landmark trials an...
The management of heart failure has changed significantly over the last 30 years, leading to improve...
Aims: Internationally, research indicates that pharmacotherapy for chronic heart failure (CHF) is su...
Heart failure (HF) is a major public health priority due to its epidemiological transition and the w...
Background: Chronic Heart Failure (CHF) has a high mortality and morbidity. Large scale randomised c...
Therapy of heart failure. The incidence and prevalence of heart failure is on the rise. It has becom...
This chapter addresses the state of knowledge in the evidence-based management of heart failure (HF)...
Background: Over the last years, several trials offered new evidence on heart failure (HF) treatment...
Heart failure (HF) is a complex clinical syndrome resulting from any structural or functional cardia...
Abstract Heart failure is one of the major problems related to heart diseases in the modern era. Mul...
International audienceHeart failure is the most common cardiovascular reason for hospital admission ...
Optimal treatment of heart failure is important to reduce hospitalization and mortality. In accordin...
Treatment of heart failure has undergone major changes in the last two decades. European and US guid...
Heart failure with reduced ejection fraction (HFrEF) is a common cardiovascular condition with a sig...
Heart failure (HF) remains a major cause of mortality, morbidity, and poor quality of life. It is an...
Major changes have occurred in these last years in heart failure (HF) management. Landmark trials an...
The management of heart failure has changed significantly over the last 30 years, leading to improve...
Aims: Internationally, research indicates that pharmacotherapy for chronic heart failure (CHF) is su...
Heart failure (HF) is a major public health priority due to its epidemiological transition and the w...
Background: Chronic Heart Failure (CHF) has a high mortality and morbidity. Large scale randomised c...